— Know what they know.
Not Investment Advice

HCAT NASDAQ

Health Catalyst, Inc.
1W: +10.3% 1M: -1.5% 3M: -27.9% YTD: -43.4% 1Y: -67.3% 3Y: -88.2% 5Y: -97.3%
$1.29
+0.00 (+0.00%)
 
Weekly Expected Move ±14.8%
$1 $1 $1 $1 $2
NASDAQ · Healthcare · Medical - Healthcare Information Services · Alpha Radar Sell · Power 37 · $95.3M mcap · 62M float · 1.20% daily turnover · Short 73% of daily vol

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

NO EDGE
37.2 / 100
NoneWeakNarrowWide
Primary source: Intangible Assets  ·  ROIC: -14.3%  ·  5Y Avg: -19.9%
Cost Advantage
48
Intangibles
50
Switching Cost
22
Network Effect
29
Scale
35
The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. HCAT has No discernible competitive edge (37.2/100). The business operates without significant structural advantages. The primary source of advantage is Intangible Assets. Negative ROIC of -14.3% indicates the company is currently destroying value, though this may reflect a growth investment phase.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets
$2
Low
$2
Avg Target
$2
High
Based on 1 analyst since May 11, 2026 earnings
Analyst Recommendations
Strong Buy: 0Buy: 12Hold: 10Sell: 0Strong Sell: 0
Rating Summary
ConsensusBuy
Avg Target$2.25
Analysts3
Price Target Change History
DateFirmAnalystOldNewChangeUpside @ CallStock@Call
2026-05-12 Stephens $5 $2 -3 +26.8% $1.38
2026-03-13 Raymond James Sarah James Initiated $3 +67.6% $1.79
2026-03-13 Canaccord Genuity Richard Close $5 $2 -3 +11.7% $1.79
2025-10-08 Evercore ISI Initiated $3 +3.4% $2.90
2025-10-08 KeyBanc $5 $4 -1 +40.4% $2.85
2025-08-29 Canaccord Genuity Richard Close $11 $5 -6 +37.0% $3.65
2025-08-29 Summit Redstone Partners Initiated $5 +37.0% $3.65
2025-04-16 KeyBanc Scott Schoenhaus Initiated $5 +33.3% $3.75
2025-03-06 Stephens $7 $5 -2 +12.9% $4.43
2025-01-14 RBC Capital Sean Dodge $35 $7 -28 +0.3% $6.98
2024-09-03 Canaccord Genuity Richard Close Initiated $11 +50.9% $7.29
2024-08-26 Piper Sandler Jessica Tassan $14 $11 -3 +53.0% $7.19
2024-08-08 Stephens Jeff Garro Initiated $7 +27.7% $5.48
2024-06-06 Piper Sandler Jessica Tassan $21 $14 -7 +109.0% $6.70
2024-01-25 Guggenheim Jack Wallace $60 $14 -46 +40.8% $9.94
2022-05-11 Piper Sandler Jessica Tassan Initiated $21 +62.2% $12.95
2022-03-01 RBC Capital Sean Dodge Initiated $35 +27.1% $27.54
2022-02-10 Goldman Sachs Cindy Motz CFA Initiated $48 +59.3% $30.14
2021-05-26 Guggenheim Sandy Draper Initiated $60 +10.6% $54.25
2021-05-06 Cantor Fitzgerald Steven Halper Initiated $60 +12.7% $53.23

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

B-
May 22, 2026
DCF
5
ROE
1
ROA
1
D/E
3
P/E
1
P/B
4
The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. HCAT receives an overall rating of B-. Strongest factors: DCF (5/5), P/B (4/5). Areas of concern: ROE (1/5), ROA (1/5), P/E (1/5).
Rating Change History
DateFromTo
2026-05-14 B B-
2026-05-11 B- B
2026-04-27 C+ B-
2026-03-16 B- C+

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

17 Grade D
Profitability
10
Balance Sheet
48
Earnings Quality
23
Growth
30
Value
33
Momentum
33
Safety
0
Cash Flow
33
The InsiderStreet Scorecard rates companies across eight dimensions: Profitability (margins, ROA, ROE), Balance Sheet (leverage, liquidity, coverage), Earnings Quality (accruals, cash conversion), Growth (revenue and earnings trajectory), Value (P/E, P/B, earnings yield, Graham criteria), Momentum (revenue and earnings acceleration), Safety (Altman Z-Score risk adjustment), and Cash Flow (operating cash flow quality, FCF conversion, cash coverage). The overall score blends 35% quality, 35% value, and 30% momentum, with a penalty for distress-zone Altman scores. HCAT scores highest in Balance Sheet (48/100) and lowest in Safety (0/100). A grade of D flags significant fundamental concerns across multiple dimensions.

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score
-3.74
Distress Zone
Piotroski F-Score
4/9
Beneish M-Score
-4.94
Unlikely Manipulator
Ohlson O-Score
-4.88
Bankruptcy prob: 0.8%
Low Risk
Credit Rating
B
Score: 29.4/100
Trend: Improving
Earnings Quality
OCF/NI: -0.07x
Accruals: -41.7%
The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. HCAT scores -3.74, placing it in the Distress Zone (safe > 2.99, distress < 1.81). Historically, companies in this range face elevated bankruptcy risk. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. HCAT scores 4/9, indicating moderate financial health — some areas of strength offset by weaknesses in others. The Beneish M-Score (1999) is an 8-variable model that detects earnings manipulation by comparing year-over-year changes in receivables, gross margins, asset quality, sales growth, depreciation, SG&A, leverage, and accruals. Scores above −1.78 statistically resemble past manipulators. HCAT's score of -4.94 falls below this threshold, suggesting earnings are unlikely to be manipulated. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. HCAT's implied 0.8% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. HCAT receives an estimated rating of B (score: 29.4/100), with a improving trend.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E
-0.35x
PEG
0.00x
P/S
0.32x
P/B
0.68x
P/FCF
10.05x
P/OCF
4.86x
EV/EBITDA
-1.80x
EV/Revenue
0.55x
EV/EBIT
-1.17x
EV/FCF
18.29x
Earnings Yield
-287.72%
FCF Yield
9.95%
Shareholder Yield
0.00%
Graham Number
Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. HCAT currently has negative earnings — the P/E ratio is not meaningful.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden
1.003
NI / EBT
×
Interest Burden
1.842
EBT / EBIT
×
EBIT Margin
-0.475
EBIT / Rev
×
Asset Turnover
0.444
Rev / Assets
×
Equity Multiplier
2.228
Assets / Equity
=
ROE
-86.8%
The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. HCAT's ROE of -86.8% is driven by Asset Turnover (0.444), indicating efficient use of assets to generate revenue. A tax burden ratio of 1.00 indicates minimal tax leakage — the company retains over 90% of pre-tax earnings.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Adj. Growth Rate
0.00%
Fair P/E
8.50x
Intrinsic Value
Price/Value
Margin of Safety
Premium
Assessment
Overvalued

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1717 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$1.29
Median 1Y
$0.63
5th Pctile
$0.22
95th Pctile
$1.81
Ann. Volatility
66.5%
Analyst Target
$2.25
25th–75th percentile 5th–95th percentile Median path Historical Analyst target

Executive Compensation

C-suite compensation breakdown including salary, stock awards, options, and incentive pay. The CEO-to-employee pay ratio and Gini coefficient measure pay distribution fairness.

C-Suite Compensation

ExecutiveSalaryStockTotal
Kevin Freeman ,
Chief Commercial Officer
$387,500 $1,564,820 $2,163,478
Benjamin Landry ,
General Counsel
$391,667 $1,066,923 $1,572,148
Linda Llewelyn ,
Chief People Officer
$373,333 $924,666 $1,409,780
Jason Alger ,
Chief Financial Officer
$338,333 $826,581 $1,287,155
Bryan Hunt Financial
ief Financial Officer
$83,750 $— $798,455

CEO Pay Ratio

Insufficient data for pay ratio.

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees
Revenue / Employee
Rev: $311,136,000
Profit / Employee
NI: $-177,974,000
SGA / Employee
Avg labor cost proxy

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
ROE -56.4% -61.8% -38.4% -36.9% -36.3% -37.7% -29.0% -31.3% -31.1% -26.1% -29.8% -26.7% -21.8% -20.0% -19.0% -19.8% -27.4% -29.4% -58.3% -86.8% -86.83%
ROA -30.6% -33.5% -21.7% -20.9% -20.6% -21.4% -17.3% -18.7% -18.6% -15.6% -16.3% -14.5% -11.9% -10.9% -8.9% -9.3% -12.8% -13.8% -26.1% -39.0% -38.96%
ROIC -46.9% -54.3% -40.3% -40.3% -40.5% -41.5% -35.7% -38.4% -38.8% -33.4% -33.6% -30.4% -25.4% -22.5% -14.7% -14.1% -18.6% -19.4% -17.6% -14.3% -14.28%
ROCE -24.1% -28.0% -19.3% -19.3% -19.4% -19.6% -20.1% -21.1% -20.9% -17.3% -18.0% -16.0% -12.9% -12.3% -11.2% -10.7% -15.2% -15.1% -37.0% -34.7% -34.75%
Gross Margin 49.6% 46.4% 47.7% 50.1% 51.0% 46.8% 44.9% 48.1% 46.1% 43.4% 40.6% 48.5% 47.2% 44.6% 43.6% 45.6% 47.4% 49.5% 52.7% 33.4% 33.43%
Operating Margin -54.2% -68.4% -69.2% -35.8% -47.0% -66.9% -53.1% -47.3% -47.3% -33.3% -43.7% -30.5% -20.8% -17.9% -22.0% -25.4% -46.0% -22.9% 4.4% -9.5% -9.54%
Net Margin -60.1% -64.8% -75.7% -33.0% -47.3% -66.9% -51.7% -44.9% -44.5% -29.9% -40.4% -27.6% -17.8% -19.3% -26.0% -29.9% -50.8% -29.1% -1.2% -1.6% -1.57%
EBITDA Margin -39.8% -51.1% -52.0% -18.2% -27.4% -44.8% -31.0% -26.5% -27.3% -12.5% -24.0% -10.9% -1.3% -8.8% -3.1% -4.9% -27.8% -5.2% -96.7% 7.6% 7.59%
FCF Margin -16.5% -17.1% -17.1% -13.4% -15.1% -17.3% -18.7% -20.5% -20.7% -14.7% -15.7% -10.1% -5.8% -5.1% -0.6% -3.1% -5.0% -7.2% -1.5% 3.0% 3.03%
OCF Margin -7.7% -7.6% -9.6% -7.4% -8.9% -11.1% -12.8% -14.9% -15.5% -10.0% -11.2% -5.8% -1.4% -0.3% 4.7% 1.5% -1.9% -4.0% 0.2% 6.3% 6.27%
ROE 3Y Avg snapshot only -52.19%
ROE 5Y Avg snapshot only -43.93%
ROA 3Y Avg snapshot only -25.42%
ROIC 3Y Avg snapshot only -13.57%
ROIC Economic snapshot only -11.17%
Cash ROA snapshot only 3.77%
Cash ROIC snapshot only 5.90%
CROIC snapshot only 2.85%
NOPAT Margin snapshot only -15.17%
Pretax Margin snapshot only -87.39%
R&D / Revenue snapshot only 14.63%
SGA / Revenue snapshot only 29.69%
SBC / Revenue snapshot only 6.44%
Valuation
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
P/E Ratio -18.52 -16.64 -13.48 -9.44 -5.37 -3.50 -4.22 -4.37 -4.75 -4.64 -4.50 -4.18 -4.38 -6.22 -6.35 -4.27 -2.62 -1.86 -0.95 -0.35 -0.353
P/S Ratio 11.54 10.63 8.54 5.47 2.93 1.94 2.10 2.30 2.46 1.98 1.80 1.49 1.27 1.63 1.44 1.00 0.83 0.63 0.55 0.30 0.315
P/B Ratio 9.02 8.88 3.95 2.66 1.49 1.01 1.36 1.52 1.65 1.35 1.45 1.20 1.03 1.34 1.21 0.85 0.72 0.55 0.69 0.38 0.678
P/FCF -69.89 -62.24 -49.77 -40.88 -19.45 -11.22 -11.20 -11.21 -11.88 -13.45 -11.44 -14.65 -21.88 -31.67 -239.81 -32.10 -16.69 -8.80 -35.43 10.05 10.054
P/OCF 30.29 67.91 232.13 4.86 4.862
EV/EBITDA -27.09 -23.14 -17.33 -11.35 -5.54 -2.98 -5.53 -5.85 -6.38 -6.53 -6.94 -6.73 -8.54 -12.51 -24.67 -22.81 -7.68 -6.44 -2.39 -1.80 -1.798
EV/Revenue 11.19 10.30 7.54 4.53 2.03 1.05 1.68 1.89 2.05 1.58 1.57 1.26 1.04 1.40 1.47 1.03 0.86 0.67 0.79 0.55 0.554
EV/EBIT -20.49 -17.33 -12.78 -8.05 -3.74 -1.97 -3.45 -3.76 -4.18 -3.95 -4.20 -3.81 -3.94 -5.62 -7.56 -5.60 -3.38 -2.62 -1.60 -1.17 -1.168
EV/FCF -67.77 -60.32 -43.98 -33.81 -13.44 -6.10 -8.96 -9.21 -9.92 -10.74 -9.96 -12.37 -17.92 -27.25 -245.39 -33.17 -17.35 -9.25 -51.20 18.29 18.288
Earnings Yield -5.4% -6.0% -7.4% -10.6% -18.6% -28.6% -23.7% -22.9% -21.1% -21.5% -22.2% -23.9% -22.8% -16.1% -15.8% -23.4% -38.1% -53.7% -1.0% -2.9% -2.88%
FCF Yield -1.4% -1.6% -2.0% -2.4% -5.1% -8.9% -8.9% -8.9% -8.4% -7.4% -8.7% -6.8% -4.6% -3.2% -0.4% -3.1% -6.0% -11.4% -2.8% 9.9% 9.95%
PEG Ratio snapshot only 0.004
EV/OCF snapshot only 8.844
EV/Gross Profit snapshot only 1.206
Shareholder Yield snapshot only 0.00%
Leverage & Solvency
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Current Ratio 3.75 3.75 5.46 5.46 5.46 5.46 5.18 5.18 5.18 5.18 4.42 4.42 4.42 4.42 1.43 1.43 1.43 1.43 1.89 1.89 1.890
Quick Ratio 3.75 3.75 5.46 5.46 5.46 5.46 5.18 5.18 5.18 5.18 4.42 4.42 4.42 4.42 1.43 1.43 1.43 1.43 1.89 1.89 1.890
Debt/Equity 0.71 0.71 0.39 0.39 0.39 0.39 0.58 0.58 0.58 0.58 0.68 0.68 0.68 0.68 1.10 1.10 1.10 1.10 0.70 0.70 0.697
Net Debt/Equity -0.27 -0.27 -0.46 -0.46 -0.46 -0.46 -0.27 -0.27 -0.27 -0.27 -0.19 -0.19 -0.19 -0.19 0.03 0.03 0.03 0.03 0.31 0.31 0.307
Debt/Assets 0.34 0.34 0.25 0.25 0.25 0.25 0.33 0.33 0.33 0.33 0.35 0.35 0.35 0.35 0.47 0.47 0.47 0.47 0.34 0.34 0.341
Debt/EBITDA -2.19 -1.90 -1.94 -2.02 -2.11 -2.13 -2.96 -2.73 -2.71 -3.53 -3.73 -4.50 -6.85 -7.36 -21.99 -28.60 -11.32 -12.29 -1.67 -1.84 -1.836
Net Debt/EBITDA 0.85 0.74 2.28 2.37 2.48 2.50 1.38 1.27 1.26 1.65 1.03 1.24 1.89 2.03 -0.56 -0.73 -0.29 -0.31 -0.74 -0.81 -0.810
Interest Coverage -7.06 -8.08 -8.25 -9.53 -11.37 -14.55 -18.57 -19.52 -19.23 -15.95 -15.16 -13.41 -10.77 -6.48 -3.50 -2.54 -3.05 -3.10 -6.31 -6.62 -6.621
Equity Multiplier 2.09 2.09 1.59 1.59 1.59 1.59 1.77 1.77 1.77 1.77 1.91 1.91 1.91 1.91 2.35 2.35 2.35 2.35 2.05 2.05 2.045
Cash Ratio snapshot only 1.069
Debt Service Coverage snapshot only -4.301
Cash to Debt snapshot only 0.559
FCF to Debt snapshot only 0.054
Defensive Interval snapshot only 286.7 days
Efficiency & Turnover
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Asset Turnover 0.49 0.52 0.34 0.36 0.38 0.39 0.35 0.36 0.36 0.37 0.41 0.41 0.41 0.42 0.39 0.40 0.41 0.41 0.46 0.44 0.444
Inventory Turnover
Receivables Turnover 5.69 6.08 4.98 5.24 5.46 5.60 5.71 5.83 5.88 5.99 5.47 5.48 5.53 5.58 5.22 5.30 5.38 5.38 5.35 5.20 5.201
Payables Turnover 24.18 26.13 24.81 26.14 27.05 27.69 31.38 32.33 33.39 34.58 29.66 29.70 29.81 29.91 18.35 18.86 19.13 18.71 15.34 15.71 15.713
DSO 64 60 73 70 67 65 64 63 62 61 67 67 66 65 70 69 68 68 68 70 70.2 days
DIO 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.0 days
DPO 15 14 15 14 13 13 12 11 11 11 12 12 12 12 20 19 19 20 24 23 23.2 days
Cash Conversion Cycle 49 46 59 56 53 52 52 51 51 50 54 54 54 53 50 50 49 48 44 47 46.9 days
Fixed Asset Turnover snapshot only 7.473
Cash Velocity snapshot only 3.160
Capital Intensity snapshot only 1.662
Growth (YoY)
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue 26.1% 28.7% 28.1% 27.4% 22.8% 17.9% 14.2% 11.0% 7.3% 6.7% 7.1% 5.2% 5.2% 4.2% 3.6% 4.9% 5.5% 4.6% 1.5% -2.8% -2.83%
Net Income -67.4% -70.7% -33.2% -17.0% -7.7% -2.3% 10.3% -0.6% -1.7% 17.9% 14.0% 28.8% 41.3% 36.0% 41.2% 31.2% -15.8% -36.0% -1.6% -2.7% -2.65%
EPS -42.2% -40.3% -8.9% 3.5% 9.9% 7.7% 14.2% 3.5% 2.5% 21.4% 18.5% 32.5% 44.6% 39.9% 45.8% 41.2% 1.4% -16.8% -1.2% -2.4% -2.45%
FCF 10.9% -1.7% -14.6% -19.1% -12.1% -19.2% -24.7% -69.9% -47.4% 9.1% 10.1% 47.9% 70.6% 63.6% 96.0% 67.9% 9.2% -46.7% -1.6% 1.9% 1.95%
EBITDA -43.4% -63.1% -25.7% -18.1% -8.7% 6.5% 20.4% 10.3% 5.5% 26.9% 20.3% 39.1% 60.3% 51.8% 72.6% 74.6% 2.2% 3.3% -4.6% -5.6% -5.63%
Op. Income -74.6% -94.4% -49.4% -40.4% -21.5% -7.4% 2.5% -4.8% -5.2% 11.6% 9.4% 23.8% 36.9% 35.0% 45.0% 41.5% 7.8% -8.4% -2.4% 13.5% 13.51%
OCF Growth snapshot only 3.15%
Asset Growth snapshot only -41.48%
Equity Growth snapshot only -32.70%
Debt Growth snapshot only -57.43%
Shares Change snapshot only 5.89%
Growth (CAGR)
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue 3Y 90.3% 49.3% 30.1% 18.4% 17.4% 16.2% 14.1% 11.5% 9.4% 8.2% 7.0% 6.0% 5.2% 4.0% 2.4% 2.36%
Revenue 5Y 50.3% 29.9% 19.4% 13.0% 12.0% 10.5% 8.7% 8.67%
EPS 3Y
EPS 5Y
Net Income 3Y
Net Income 5Y
EBITDA 3Y
EBITDA 5Y
Gross Profit 3Y 85.6% 46.2% 28.4% 16.5% 15.5% 13.2% 10.5% 7.7% 6.4% 6.2% 4.6% 3.4% 3.4% 4.4% 1.1% 1.09%
Gross Profit 5Y 45.7% 27.0% 17.2% 11.3% 11.4% 10.8% 7.2% 7.21%
Op. Income 3Y
Op. Income 5Y
FCF 3Y
FCF 5Y
OCF 3Y
OCF 5Y
Assets 3Y 95.7% 35.5% 35.5% 35.5% 35.5% 6.7% 6.7% 6.7% 6.7% 1.1% 1.1% 1.1% 1.1% -12.6% -12.6% -12.58%
Assets 5Y 44.6% 23.2% 23.2% 23.2% 23.2% -2.7% -2.7% -2.75%
Equity 3Y 28.4% 28.4% 28.4% 28.4% 9.9% 9.9% 9.9% 9.9% -11.2% -11.2% -11.2% -11.2% -16.7% -16.7% -16.69%
Book Value 3Y 12.4% 12.3% 13.0% 14.6% -0.5% -0.2% 0.2% 2.5% -16.4% -18.4% -18.6% -18.6% -23.7% -23.8% -23.83%
Dividend 3Y
Growth Quality
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue Stability 0.93 0.96 0.99 1.00 0.91 0.94 0.97 0.97 0.96 0.96 0.93 0.92 0.86 0.87 0.89 0.92 0.90 0.87 0.81 0.810
Earnings Stability 1.00 0.96 0.91 0.87 0.90 0.72 0.78 0.75 0.63 0.43 0.26 0.01 0.19 0.04 0.00 0.01 0.05 0.00 0.12 0.122
Margin Stability 0.95 0.96 0.99 0.99 0.96 0.97 0.98 0.97 0.97 0.96 0.96 0.95 0.94 0.94 0.95 0.96 0.97 0.96 0.96 0.959
Rev. Growth Consistency 0.50 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.00 0.000
Earn. Growth Consistency 0.00 0.00 0.00 0.00 0.00 0.00 0.50 0.00 0.00 0.50 1.00 0.50 0.50 1.00 1.00 1.00 0.00 0.00 0.00 0.00 0.000
FCF Positive Streak 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Earnings Persistence 0.50 0.87 0.93 0.97 0.99 0.96 1.00 0.99 0.93 0.94 0.88 0.83 0.86 0.84 0.88 0.94 0.86 0.50 0.50 0.500
Earnings Smoothness
ROE Trend 0.00 0.08 0.17 0.19 0.03 0.02 0.04 0.12 -0.01 0.03 0.08 0.07 0.13 0.12 0.02 -0.04 -0.47 -0.84 -0.836
Gross Margin Trend -0.01 -0.01 -0.01 -0.01 0.00 -0.00 -0.01 -0.03 -0.03 -0.04 -0.03 -0.03 -0.02 -0.00 -0.01 -0.00 0.01 0.04 0.01 0.010
FCF Margin Trend 0.02 0.05 0.09 0.05 0.02 -0.01 -0.07 -0.05 0.02 0.02 0.07 0.12 0.11 0.17 0.12 0.08 0.03 0.07 0.10 0.097
Sustainable Growth Rate
Internal Growth Rate
Cash Flow Quality
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
OCF/Net Income 0.12 0.12 0.15 0.13 0.16 0.20 0.26 0.28 0.30 0.23 0.28 0.16 0.05 0.01 -0.21 -0.06 0.06 0.12 -0.00 -0.07 -0.071
FCF/OCF 2.15 2.25 1.79 1.81 1.70 1.55 1.47 1.38 1.34 1.48 1.41 1.75 4.28 16.26 -0.13 -2.12 2.61 1.79 -6.55 0.48 0.484
FCF/Net Income snapshot only -0.035
CapEx/Revenue 8.8% 9.5% 7.6% 6.0% 6.2% 6.2% 6.0% 5.6% 5.2% 4.8% 4.5% 4.3% 4.4% 4.8% 5.3% 4.6% 3.1% 3.2% 1.8% 3.2% 3.24%
CapEx/Depreciation snapshot only 0.195
Accruals Ratio -0.27 -0.29 -0.18 -0.18 -0.17 -0.17 -0.13 -0.13 -0.13 -0.12 -0.12 -0.12 -0.11 -0.11 -0.11 -0.10 -0.12 -0.12 -0.26 -0.42 -0.417
Sloan Accruals snapshot only -0.162
Cash Flow Adequacy snapshot only 1.936
Dividends & Buybacks
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Dividend Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Dividend/Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Payout Ratio
FCF Payout Ratio 0.0% 0.00%
Total Payout Ratio
Div. Increase Streak
Chowder Number
Buyback Yield 0.0% 0.0% 0.0% 0.0% 0.0% 1.6% 1.4% 1.6% 1.5% 0.3% 0.3% 0.0% 0.0% 0.0% 0.0% 1.6% 1.9% 2.5% 2.9% 0.0% 0.00%
Net Buyback Yield -0.3% -0.3% -0.2% -0.3% -0.5% 0.8% 1.3% 1.5% 1.2% -0.2% -0.2% -0.8% -0.8% -0.5% -0.6% 0.8% 1.1% 1.6% 2.1% -1.3% -1.32%
Total Shareholder Return -0.3% -0.3% -0.2% -0.3% -0.5% 0.8% 1.3% 1.5% 1.2% -0.2% -0.2% -0.8% -0.8% -0.5% -0.6% 0.8% 1.1% 1.6% 2.1% -1.3% -1.32%
DuPont Factors
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Tax Burden (NI/EBT) 1.00 0.96 0.96 0.93 0.93 0.97 0.97 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.01 1.00 1.01 1.00 1.00 1.003
Interest Burden (EBT/EBIT) 1.14 1.12 1.12 1.10 1.09 1.07 1.05 1.05 1.05 1.06 1.07 1.07 1.09 1.05 1.16 1.26 1.23 1.32 1.16 1.84 1.842
EBIT Margin -0.55 -0.59 -0.59 -0.56 -0.54 -0.53 -0.49 -0.50 -0.49 -0.40 -0.37 -0.33 -0.26 -0.25 -0.19 -0.18 -0.26 -0.26 -0.49 -0.47 -0.475
Asset Turnover 0.49 0.52 0.34 0.36 0.38 0.39 0.35 0.36 0.36 0.37 0.41 0.41 0.41 0.42 0.39 0.40 0.41 0.41 0.46 0.44 0.444
Equity Multiplier 1.85 1.85 1.77 1.77 1.77 1.77 1.67 1.67 1.67 1.67 1.84 1.84 1.84 1.84 2.13 2.13 2.13 2.13 2.23 2.23 2.228
Per Share
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
EPS (Diluted TTM) $-3.00 $-3.00 $-2.94 $-2.77 $-2.70 $-2.77 $-2.52 $-2.67 $-2.63 $-2.18 $-2.06 $-1.80 $-1.46 $-1.31 $-1.11 $-1.06 $-1.44 $-1.53 $-2.51 $-3.65 $-3.65
Book Value/Share $6.15 $5.63 $10.02 $9.81 $9.73 $9.61 $7.80 $7.66 $7.59 $7.49 $6.38 $6.26 $6.19 $6.07 $5.85 $5.33 $5.25 $5.19 $3.46 $3.39 $1.90
Tangible Book/Share $1.55 $1.42 $4.75 $4.65 $4.61 $4.55 $2.69 $2.65 $2.62 $2.59 $1.79 $1.76 $1.73 $1.70 $0.31 $0.28 $0.28 $0.28 $-0.58 $-0.56 $-0.56
Revenue/Share $4.81 $4.70 $4.64 $4.78 $4.94 $5.00 $5.07 $5.08 $5.08 $5.11 $5.15 $5.07 $5.05 $5.00 $4.92 $4.54 $4.54 $4.49 $4.38 $4.17 $4.17
FCF/Share $-0.79 $-0.80 $-0.80 $-0.64 $-0.74 $-0.86 $-0.95 $-1.04 $-1.05 $-0.75 $-0.81 $-0.51 $-0.29 $-0.26 $-0.03 $-0.14 $-0.23 $-0.32 $-0.07 $0.13 $0.13
OCF/Share $-0.37 $-0.36 $-0.44 $-0.35 $-0.44 $-0.56 $-0.65 $-0.76 $-0.79 $-0.51 $-0.58 $-0.29 $-0.07 $-0.02 $0.23 $0.07 $-0.09 $-0.18 $0.01 $0.26 $0.26
Cash/Share $6.03 $5.53 $8.54 $8.36 $8.29 $8.19 $6.67 $6.55 $6.49 $6.41 $5.53 $5.42 $5.36 $5.26 $6.28 $5.72 $5.63 $5.57 $1.35 $1.32 $1.50
EBITDA/Share $-1.99 $-2.09 $-2.02 $-1.90 $-1.81 $-1.77 $-1.54 $-1.64 $-1.64 $-1.24 $-1.16 $-0.94 $-0.61 $-0.56 $-0.29 $-0.21 $-0.51 $-0.47 $-1.44 $-1.28 $-1.28
Debt/Share $4.35 $3.99 $3.93 $3.84 $3.81 $3.77 $4.55 $4.47 $4.43 $4.37 $4.33 $4.25 $4.20 $4.12 $6.45 $5.87 $5.78 $5.72 $2.41 $2.36 $2.36
Net Debt/Share $-1.68 $-1.54 $-4.61 $-4.52 $-4.48 $-4.43 $-2.12 $-2.08 $-2.06 $-2.04 $-1.19 $-1.17 $-1.16 $-1.14 $0.16 $0.15 $0.15 $0.15 $1.06 $1.04 $1.04
Academic Models
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Altman Z-Score -3.736
Altman Z-Prime snapshot only -9.352
Piotroski F-Score 3 2 4 5 6 5 3 2 2 3 3 4 4 4 5 4 3 3 5 4 4
Beneish M-Score -1.71 -1.72 -3.06 -3.05 -3.05 -3.06 -3.04 -3.17 -3.07 -2.95 -2.75 -2.82 -2.77 -2.78 -2.89 -2.79 -2.91 -3.06 -4.18 -4.94 -4.936
Ohlson O-Score snapshot only -4.882
Net-Net WC snapshot only $-1.21
EVA snapshot only $-78019700.00
Credit
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Credit Rating snapshot only B
Credit Score 52.03 52.26 50.05 40.59 37.36 32.42 32.19 32.17 32.38 32.63 32.24 32.34 31.84 31.93 24.73 24.82 23.41 24.00 27.23 29.38 29.381
Credit Grade snapshot only 15
Credit Trend snapshot only 4.562
Implied Spread (bps) snapshot only 750.000
Industry Credit Rank snapshot only 21
Sector Credit Rank snapshot only 17

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms